| Paul Allan Jabour, MD | |
|
12368 Stratford Dr Ste 300, Clive, IA 50325 | |
| (515) 226-2122 | |
| Not Available |
| Full Name | Paul Allan Jabour |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 13 Years |
| Location | 12368 Stratford Dr Ste 300, Clive, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1891089868 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 44317 (Iowa) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Unitypoint Health - Des Moines Iowa Methodist Medi | Des moines, IA | Hospital |
| Grinnell Regional Medical Center | Grinnell, IA | Hospital |
| St Anthony Regional Hospital & Nursing Home | Carroll, IA | Hospital |
| Trinity Regional Medical Center | Fort dodge, IA | Hospital |
| Mahaska Health Partnership | Oskaloosa, IA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Iowa Diagnostic Imaging And Procedure Center, L C | 1658263546 | 34 |
| Iowa Radiology P C | 2264323468 | 37 |
| Des Moines University Osteopathic Medical Center | 6002713443 | 34 |
News Archive
A review of epidemiological data has found evidence that people who spend fewer years in school may experience a slight but statistically significant delay in the realization that they're having cognitive problems that could be Alzheimer's disease.
In a unique collaborative paper in PLoS Medicine , Georgetown University Medical Center's Adriane Fugh-Berman and a former Eli Lilly drug rep reveal the tactics used by drug reps to manipulate physicians into selling drugs.
Today, Insilico Medicine, Inc., a company applying the latest advances in deep learning to biomarker development, drug discovery and aging research, launched ALS.AI, a personalized drug discovery and biomarker development platform utilizing the latest advances in deep learning.
Pearl Therapeutics Inc., a company developing clinically differentiated combination therapies for the treatment of highly prevalent chronic respiratory diseases, today announced positive results from a Phase 1 safety and pharmacokinetics study of PT003, its lead combination therapeutic for the treatment of chronic obstructive pulmonary disease (COPD). Based on these results, and previously announced positive results from Phase 2a studies of PT003's individual components, the company has advanced PT003 into a Phase 2b trial.
› Verified 2 days ago
| Entity Name | Trinity Regional Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073594156 PECOS PAC ID: 7315858529 Enrollment ID: O20031204000921 |
News Archive
A review of epidemiological data has found evidence that people who spend fewer years in school may experience a slight but statistically significant delay in the realization that they're having cognitive problems that could be Alzheimer's disease.
In a unique collaborative paper in PLoS Medicine , Georgetown University Medical Center's Adriane Fugh-Berman and a former Eli Lilly drug rep reveal the tactics used by drug reps to manipulate physicians into selling drugs.
Today, Insilico Medicine, Inc., a company applying the latest advances in deep learning to biomarker development, drug discovery and aging research, launched ALS.AI, a personalized drug discovery and biomarker development platform utilizing the latest advances in deep learning.
Pearl Therapeutics Inc., a company developing clinically differentiated combination therapies for the treatment of highly prevalent chronic respiratory diseases, today announced positive results from a Phase 1 safety and pharmacokinetics study of PT003, its lead combination therapeutic for the treatment of chronic obstructive pulmonary disease (COPD). Based on these results, and previously announced positive results from Phase 2a studies of PT003's individual components, the company has advanced PT003 into a Phase 2b trial.
› Verified 2 days ago
| Entity Name | Des Moines Orthopaedic Surgeons Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255405221 PECOS PAC ID: 0345141719 Enrollment ID: O20040119000163 |
News Archive
A review of epidemiological data has found evidence that people who spend fewer years in school may experience a slight but statistically significant delay in the realization that they're having cognitive problems that could be Alzheimer's disease.
In a unique collaborative paper in PLoS Medicine , Georgetown University Medical Center's Adriane Fugh-Berman and a former Eli Lilly drug rep reveal the tactics used by drug reps to manipulate physicians into selling drugs.
Today, Insilico Medicine, Inc., a company applying the latest advances in deep learning to biomarker development, drug discovery and aging research, launched ALS.AI, a personalized drug discovery and biomarker development platform utilizing the latest advances in deep learning.
Pearl Therapeutics Inc., a company developing clinically differentiated combination therapies for the treatment of highly prevalent chronic respiratory diseases, today announced positive results from a Phase 1 safety and pharmacokinetics study of PT003, its lead combination therapeutic for the treatment of chronic obstructive pulmonary disease (COPD). Based on these results, and previously announced positive results from Phase 2a studies of PT003's individual components, the company has advanced PT003 into a Phase 2b trial.
› Verified 2 days ago
| Entity Name | Des Moines University Osteopathic Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164475760 PECOS PAC ID: 6002713443 Enrollment ID: O20040226000810 |
News Archive
A review of epidemiological data has found evidence that people who spend fewer years in school may experience a slight but statistically significant delay in the realization that they're having cognitive problems that could be Alzheimer's disease.
In a unique collaborative paper in PLoS Medicine , Georgetown University Medical Center's Adriane Fugh-Berman and a former Eli Lilly drug rep reveal the tactics used by drug reps to manipulate physicians into selling drugs.
Today, Insilico Medicine, Inc., a company applying the latest advances in deep learning to biomarker development, drug discovery and aging research, launched ALS.AI, a personalized drug discovery and biomarker development platform utilizing the latest advances in deep learning.
Pearl Therapeutics Inc., a company developing clinically differentiated combination therapies for the treatment of highly prevalent chronic respiratory diseases, today announced positive results from a Phase 1 safety and pharmacokinetics study of PT003, its lead combination therapeutic for the treatment of chronic obstructive pulmonary disease (COPD). Based on these results, and previously announced positive results from Phase 2a studies of PT003's individual components, the company has advanced PT003 into a Phase 2b trial.
› Verified 2 days ago
| Entity Name | Iowa Radiology P C |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336107283 PECOS PAC ID: 2264323468 Enrollment ID: O20040324001052 |
News Archive
A review of epidemiological data has found evidence that people who spend fewer years in school may experience a slight but statistically significant delay in the realization that they're having cognitive problems that could be Alzheimer's disease.
In a unique collaborative paper in PLoS Medicine , Georgetown University Medical Center's Adriane Fugh-Berman and a former Eli Lilly drug rep reveal the tactics used by drug reps to manipulate physicians into selling drugs.
Today, Insilico Medicine, Inc., a company applying the latest advances in deep learning to biomarker development, drug discovery and aging research, launched ALS.AI, a personalized drug discovery and biomarker development platform utilizing the latest advances in deep learning.
Pearl Therapeutics Inc., a company developing clinically differentiated combination therapies for the treatment of highly prevalent chronic respiratory diseases, today announced positive results from a Phase 1 safety and pharmacokinetics study of PT003, its lead combination therapeutic for the treatment of chronic obstructive pulmonary disease (COPD). Based on these results, and previously announced positive results from Phase 2a studies of PT003's individual components, the company has advanced PT003 into a Phase 2b trial.
› Verified 2 days ago
| Entity Name | Iowa Diagnostic Imaging & Procedure Center, L C |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528026481 PECOS PAC ID: 1658263546 Enrollment ID: O20040325001707 |
News Archive
A review of epidemiological data has found evidence that people who spend fewer years in school may experience a slight but statistically significant delay in the realization that they're having cognitive problems that could be Alzheimer's disease.
In a unique collaborative paper in PLoS Medicine , Georgetown University Medical Center's Adriane Fugh-Berman and a former Eli Lilly drug rep reveal the tactics used by drug reps to manipulate physicians into selling drugs.
Today, Insilico Medicine, Inc., a company applying the latest advances in deep learning to biomarker development, drug discovery and aging research, launched ALS.AI, a personalized drug discovery and biomarker development platform utilizing the latest advances in deep learning.
Pearl Therapeutics Inc., a company developing clinically differentiated combination therapies for the treatment of highly prevalent chronic respiratory diseases, today announced positive results from a Phase 1 safety and pharmacokinetics study of PT003, its lead combination therapeutic for the treatment of chronic obstructive pulmonary disease (COPD). Based on these results, and previously announced positive results from Phase 2a studies of PT003's individual components, the company has advanced PT003 into a Phase 2b trial.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Paul Allan Jabour, MD 4200 University Ave Ste 104, West Des Moines, IA 50266-5945 Ph: (515) 226-2122 | Paul Allan Jabour, MD 12368 Stratford Dr Ste 300, Clive, IA 50325 Ph: (515) 226-2122 |
News Archive
A review of epidemiological data has found evidence that people who spend fewer years in school may experience a slight but statistically significant delay in the realization that they're having cognitive problems that could be Alzheimer's disease.
In a unique collaborative paper in PLoS Medicine , Georgetown University Medical Center's Adriane Fugh-Berman and a former Eli Lilly drug rep reveal the tactics used by drug reps to manipulate physicians into selling drugs.
Today, Insilico Medicine, Inc., a company applying the latest advances in deep learning to biomarker development, drug discovery and aging research, launched ALS.AI, a personalized drug discovery and biomarker development platform utilizing the latest advances in deep learning.
Pearl Therapeutics Inc., a company developing clinically differentiated combination therapies for the treatment of highly prevalent chronic respiratory diseases, today announced positive results from a Phase 1 safety and pharmacokinetics study of PT003, its lead combination therapeutic for the treatment of chronic obstructive pulmonary disease (COPD). Based on these results, and previously announced positive results from Phase 2a studies of PT003's individual components, the company has advanced PT003 into a Phase 2b trial.
› Verified 2 days ago
Andrew David Nish, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 12368 Stratford Dr, Suite 300, Clive, IA 50325 Phone: 515-226-9810 Fax: 515-226-8408 | |
Dr. James H Jacobs Jr., MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 12368 Stratford Dr, Suite 300, Clive, IA 50325 Phone: 515-226-9810 Fax: 515-961-2714 | |
John Rizzi, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 12368 Stratford Dr, Suite 300, Clive, IA 50325 Phone: 515-226-9810 Fax: 515-226-8408 | |
Dr. Aaron Christopher Hurlbut, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 12368 Stratford Dr, Suite 300, Clive, IA 50325 Phone: 402-560-2691 | |
David Lawrence Lacey, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 12368 Stratford Dr, Suite 300, Clive, IA 50325 Phone: 515-226-9810 Fax: 515-226-8408 | |
Stuart Kent Lehr, M.D. Radiology Medicare: Not Enrolled in Medicare Practice Location: 12368 Stratford Dr, Suite 300, Clive, IA 50325 Phone: 515-226-9810 Fax: 515-226-8408 | |
Charles Nathaniel Heggen, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 12368 Stratford Dr, Suite 300, Clive, IA 50325 Phone: 515-226-9810 Fax: 515-226-8408 |